Animal Models for HIV Cure Research by Benjamin B. Policicchio et al.
January 2016 | Volume 7 | Article 121
Review
published: 28 January 2016
doi: 10.3389/fimmu.2016.00012
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Lucy Dorrell, 
University of Oxford, UK
Reviewed by: 
Domenico Mavilio, 
University of Milan, Italy 
Alka Khaitan, 
New York University School of 
Medicine, USA 
Nilu Goonetilleke, 
University of North Carolina, USA
*Correspondence:
Ivona Pandrea  
pandrea@pitt.edu
Specialty section: 
This article was submitted to 
HIV and AIDS, 
a section of the journal 
Frontiers in Immunology
Received: 30 September 2015
Accepted: 12 January 2016
Published: 28 January 2016
Citation: 
Policicchio BB, Pandrea I and 
Apetrei C (2016) Animal Models for 
HIV Cure Research. 
Front. Immunol. 7:12. 
doi: 10.3389/fimmu.2016.00012
Animal Models for Hiv Cure 
Research
Benjamin B. Policicchio , Ivona Pandrea* and Cristian Apetrei
Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA
The HIV-1/AIDS pandemic continues to spread unabated worldwide, and no vaccine 
exists within our grasp. Effective antiretroviral therapy (ART) has been developed, but 
ART cannot clear the virus from the infected patient. A cure for HIV-1 is badly needed 
to stop both the spread of the virus in human populations and disease progression 
in infected individuals. A safe and effective cure strategy for human immunodeficiency 
virus (HIV) infection will require multiple tools, and appropriate animal models are tools 
that are central to cure research. An ideal animal model should recapitulate the essential 
aspects of HIV pathogenesis and associated immune responses, while permitting inva-
sive studies, thus allowing a thorough evaluation of strategies aimed at reducing the size 
of the reservoir (functional cure) or eliminating the reservoir altogether (sterilizing cure). 
Since there is no perfect animal model for cure research, multiple models have been 
tailored and tested to address specific quintessential questions of virus persistence and 
eradication. The development of new non-human primate and mouse models, along 
with a certain interest in the feline model, has the potential to fuel cure research. In this 
review, we highlight the major animal models currently utilized for cure research and the 
contributions of each model to this goal.
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iNTRODUCTiON
Human immunodeficiency virus (HIV) infection in humans induces massive and continuous 
depletion of CD4+ T cells, resulting in immune suppression, which, in the absence of antiretroviral 
therapy (ART), culminates with the development of the acquired immunodeficiency syndrome 
(AIDS) and death in all HIV-infected patients. As such, the burden of the HIV epidemic, which 
spreads unabated such that for every HIV-infected person, two new people become infected, calls 
for a cure for HIV (1).
The advent of ART is one of the most prominent accomplishments of modern medicine, provid-
ing relief to HIV-infected patients through effective suppression of viremia and drastically improving 
their quality of life. However, life expectancy is not fully restored in HIV-infected patients on ART 
(2). Furthermore, ART requires life-long adherence, thus preventing effective treatment from being 
delivered in a sustainable way to all in need; is associated with short- and long-term toxicity; does not 
completely restore immune integrity; is not curative; and does not eradicate HIV-1 from the infected 
patients. Studies have shown that residual HIV persists virtually indefinitely, even in patients receiv-
ing ART, and that this persistent reservoir virus is replication-competent (3). The infected cells that 
form the reservoirs, such as resting memory CD4+ T lymphocytes (1, 4, 5), are refractory to ART and 
are invisible to HIV-specific immune responses (6–8). Moreover, the anatomic sites of the reservoirs 
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are diffuse, with multiple tissues containing latent virus, including 
brain (9, 10), adipose tissue (11), spleen, lung, and other organs 
(12, 13). To further complicate the matter, unconventional cell 
types besides resting memory CD4+ T cells (such as T follicular 
helper, T memory stem cells, and T regulatory cells) have been 
identified as being latently infected (14–17). It has also been 
reported that non-T cell innate cell sets may contribute to the 
latent reservoir, such as monocytes/macrophages and dendritic 
cells (18–25), but these innate reservoirs are controversial (26). 
The tissue and cellular complexity of the viral reservoir results in 
a minimal impact of ART on the latent reservoir, even in patients 
receiving prolonged ART for over a decade (27–30). Removal of 
ART from treated patients systematically results in viral rebound, 
even in cases when therapy is initiated very early after infection 
(28, 31, 32). Rebounding virus may reseed the virus reservoirs 
and may carry drug resistance mutations (33, 34). Therefore, due 
to these potentially daunting effects of ART cessation, the current 
paradigm is that once initiated, ART should be maintained for 
life (1).
In addition to these limitations of ART, the low levels of 
residual viral replication observed in HIV-infected patients 
receiving therapy are most likely the main reason for the residual 
immune activation and inflammation observed during infection 
(35). Immune activation and inflammation are associated with 
comorbidities, accelerated aging, and mortality (36, 37). These 
issues, along with a limited availability of invasive samples from 
multiple potential reservoir sites necessary for a proper char-
acterization of the reservoir, significantly impact our ability to 
cure HIV.
Multiple lines of documented evidence unequivocally support 
the fact that ART alone cannot cure HIV infection, which are as 
follows: (i) ART intensification does not impact the viral reservoir 
(27, 38, 39); (ii) the functionally cured “Mississippi baby” (40), in 
which a very aggressive therapy was initiated very early during 
infection and was maintained for 1.5 years, experienced a massive 
virus rebound after controlling the virus for over 2 years following 
cessation of ART (29); (iii) short-course ART in acutely infected 
subjects had a minimal impact on the reservoir (30); and (iv) 
cytotoxic T lymphocytes (CTLs) are necessary to eliminate the 
virus in patients receiving ART (41). Nevertheless, a small fraction 
of patients in which ART was initiated very early during infection 
and maintained for a long period of time (largely exceeding the 
half-life of the major reservoir cell populations) was reported 
to be able to robustly and persistently control viral replication 
at the cessation of ART (42, 43). Yet, since these posttreatment 
controllers only represent a small fraction of patients and the 
correlates of virus control in these patients are not completely 
understood, there is consensus in the field that the strategies for 
virus eradication should involve therapeutic approaches that go 
beyond ART (1).
In the aftermath of the reports of the cured HIV infection in 
the “Berlin patient” (44), cure research focused around develop-
ing a “sterilizing cure” (i.e., aimed at the complete elimination 
of the virus from the infected patient). Yet, it soon became clear 
that dissecting the key factor driving HIV cure in the “Berlin 
patient” (i.e., stem cell transplantation, radiation, immune 
therapy, or graft-versus-host disease) is very challenging. 
Furthermore, studies revolving around the cure in the Berlin 
patient emphasize the complexity of this process and suggest 
that an intricate action of multiple factors may have led to the 
positive outcome in this patient. This was seen in the “Boston 
patients,” two HIV-1 positive men that received hematopoietic 
stem cell transplants from donors with wild-type-CCR5+ cells 
in an attempt to provide a sterilizing cure for HIV (45). While 
in the initial posttransplant stages (when patients were still on 
ART), there was no evidence of residual infection, both men 
exhibited rebound of virus after ART interruption (46). This 
clearly suggests that a cure approach might be a difficult enter-
prise, and therefore, a more realistic alternative to the sterilizing 
cure is the development of a “functional cure,” whereby the viral 
reservoir is reduced enough to permit cessation of ART without 
risking viral rebound (40, 45).
All these various approaches toward the HIV cure cannot be 
directly tested in humans without major risks, making impera-
tive for cure research the use of animal models that mimic HIV 
infection. In addition to providing in  vivo systems that enable 
detailed studies of the multiple anatomic reservoirs through 
invasive sampling, the animal models of cure research also permit 
refining the system in order to deconvolute different components 
that are largely intricated in humans, which prevent our complete 
understanding of the correlates of viral control. Finally, animal 
models permit interventions aimed at depleting various arms 
of the immune system or specific immune cell populations that 
might drive formation of the reservoir or enable virus persistence. 
Altogether, use of the animal models appears to be mandatory for 
the very complex field of cure research and has the potential to 
significantly advance the field.
The most commonly used animal models for cure research are 
non-human primates (NHPs), humanized mice, and to a lesser 
degree, felines, each infected with their respective immunode-
ficiency virus. Though none of these models exactly match HIV 
infection in humans, each model can be tailored to address the 
key specific questions of cure research. This review will present 
the currently available animal models for cure research, along 
with their advantages and disadvantages (Table 1), and will focus 
on the contributions that each of these models have made to the 
cure field.
NHP MODeLS FOR CURe ReSeARCH: 
STRAiNS, SYSTeMS, AND LiMiTATiONS
Non-human primates are the most widely used animal models 
for AIDS research due to the variety of disease states that can be 
induced in various NHP species by a plethora of simian immuno-
deficiency virus (SIV) strains (Table 2). Studies in NHPs helped 
define key paradigms of HIV infection pathogenesis, have been 
used in testing various therapies, and are essential for the develop-
ment of AIDS vaccines (53, 54). The NHP model of AIDS is one 
of the best animal models for infectious diseases, as it shares a lot 
of key features with HIV-1-infected humans, including anatomy, 
physiology, immune system, infectious agents, and susceptibility 
to antiretroviral treatments (55). Furthermore, due to their large 
size, NHPs allow for the frequent collection of relatively large 
volumes of samples.
TABLe 1 | Advantages and disadvantages of the major animal models for 
Hiv cure research.a
NHP/Siv or 
SHiv
Murine/
Hiv
Feline/
Fiv
Sample size +++ + ++
Anatomy compared to humans Similar Different Different
Similarity of virus to HIV Different Same Different
Infection characteristics compared to 
human/HIV
Similar Similar Different
Availability for experimental infection in 
controlled conditions vis-à-vis route and 
dose of virus inoculation, drug regimens
Yes Yes Yes
Ability to deplete arms of immune system Yes Yes Yes
Outbred Yes No Yes
Major surgery required to generate the 
model
No Yes No
Development of graft-versus-host 
disease
No Yes No
Reservoir comparison to human/HIV Similar Similar Different
Cost to maintain +++ ++ ++
aFauci and Desrosiers (47), Evans and Silvestri (48), Del Prete and Lifson (49), Akkina 
(50), McDonnel et al. (51), and Apetrei et al. (52).
TABLe 2 | Different NHP/Siv models used in cure research.a
Non-human 
primate 
species
Siv strains Acute vLs Chronic vLs Spontaneous 
elite control?
Rapid progression 
(frequency of RP)
Control with 
conventional ART
Use of 
NNRTi
Chronic 
immune 
activation
Indian rhesus 
macaque
SIVmac251/239 107–109 104–107 Yes (for specific  
MHC types)
30–40% Requires complex 
combinations
No Yes
SIVsmm 107–108 102–105 Yes (for specific  
Trim genotypes)
No Yes No Yes
SIVagmSab 106–109 <3–100 100% No No data No No
RT-SHIV 105–108 103–106 Yes (for specific  
MHC types)
No Requires complex 
combinations
Yes Yes
Chinese 
rhesus 
macaque
SIVmac239 105–107 10–105 Yes (~33%) No Yes No Yes
Pigtailed 
macaque
SIVmac251/239 105–109 103–106 Rare 30–40% Requires complex 
combinations
No Yes
SIVsmm 105–109 104–107 No >75% Requires complex 
combinations
No Yes
SIVagmSab 107–109 104–106 No 30–40% No data No Yes
RT-SHIV 104–107 103–105 Rare >75% Yes Yes Yes
Cynomolgus 
macaque
SIVmac251/239 106–108 102–105 Yes (~30%) No Yes No No data
aHaase (56), Lackner and Veazey (57), Demberg et al. (58), Horiike et al. (59), Pandrea et al. (60), Ma et al. (61), Uberla et al. (62), North et al. (12), North et al. (63), Kauffman et al. 
(64), Monceaux et al. (65), Ling et al. (66), Ling et al. (67), Klatt et al. (68), Dinoso et al. (27), Canary et al. (69), Hirsch et al. (70), Mandell et al. (71), Kristoff et al. (72), Ambrose et al. 
(73), Shao et al. (74), Kearney et al. (75), Kline et al. (13), Benlhassan-Chahour et al. (76), Mannioui et al. (77), Sellier et al. (78), Reimann et al. (79), and Budde et al. (80).
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Administration of SIV to multiple macaque species typically 
results in a persistent pathogenic infection in which progression 
to AIDS occurs in a similar fashion to HIV-infected patients 
(47). Of the wide variety of macaque species, HIV-1 research has 
focused on rhesus macaques (RMs) (Macaca mulatta), of both 
Indian and Chinese origin, pigtailed macaques (PTMs) (Macaca 
nemestrina), and cynomolgus macaques (CMs, the crab-eating 
macaque) (Macaca fascicularis). All these three macaque species 
are susceptible to infection by various SIV strains, and the disease 
outcome varies from elite-controlled infection, with a small rate 
of disease progression to AIDS-defining illnesses to a very rapid 
disease progression, with death occurring within a few months 
following infection. This variability of the disease outcomes is 
dependent on the viral strains used for challenge, on macaque 
species, and on genetic pedigree of the individual monkeys 
(48, 49). In addition to these different macaque species, HIV-1 
research has also utilized African NHPs that are natural hosts 
of SIVs, such as African green monkeys (AGMs) (Chlorocebus 
genus), sooty mangabeys (Cercocebus atys), and mandrills 
(Mandrillus sphinx). SIV infection of these species generally does 
not progress to AIDS, therefore permitting comparative studies 
aimed at identifying the correlates of immune protection and the 
lack of disease progression (81–84).
Simian immunodeficiency virus infection of macaques shares 
the key pathogenic features with HIV infection in humans, 
which make macaques an ideal environment for cure research. 
Particularly, SIVs and HIV share the following key features of 
virus persistence: (i) both HIV and SIV DNA are integrated in 
the target cell genome (85, 86) and with a similar preference to 
integration site (87). (ii) Response to interferons results in tran-
scriptional control of virus long terminal repeats (LTRs) through 
a bias of histone acetylation favoring HIV/SIV DNA persistence 
(88). (iii) Costimulatory signals can induce latent HIV/SIV 
without coengagement of T-cell receptors (89). (iv) Distribution 
of cells containing HIV and SIV DNA and RNA sequences in 
peripheral blood, lymph nodes (LNs), and at mucosal sites are 
similar in humans and macaques (77, 78, 90). (v) CTLs are 
ineffective in clearing infected cells long term due to resistance 
mutations in HIV/SIV (91, 92). These characteristics underline 
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similar reservoir dynamics in HIV- and SIV-infected humans and 
macaques, respectively.
In addition to these shared features between SIV infection in 
macaques and HIV infection in humans, there are also several 
notable differences between the two models that limit the use of 
the macaque model and call for its improvement. Of these, the 
most critical for cure research are the overall higher viral loads 
(VLs), during both acute and chronic infections, and the natural 
resistance to non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), which is a common feature of HIV-2 and SIV strains 
(93–95). Due to these features, SIV infection is more difficult 
to control with ART in macaques compared to HIV infection, 
requiring more potent combinations to achieve suppression (53, 
96–98). This limitation can be addressed by using unadapted 
SIVsmm strains in macaques, which more closely reproduces the 
pathogenesis of HIV infection in humans and are less pathogenic 
than SIVmac strains (99), with the caveat that these newly devel-
oped strains are less characterized than the reference SIVmac 
strains.
Another notable difference between HIV and SIV infection 
regards their relations with the enzyme SAM domain and HD 
domain 1 (SAMHD1). SAMHD1 is a nuclear protein with phos-
phohydrolase activity that can restrict replication of lentiviruses 
by depleting the nucleotriphosphate (NTP) pool during reverse 
transcription (100). SAMHD1 is involved in HIV-1 restriction 
in non-dividing, resting T cells that do not support productive 
virus replication and is a key component of the reservoir. The viral 
accessory protein Vpx, which antagonizes SAMHD1 activity, has 
no effect on the infection of activated T cells but relieves the block 
to reverse transcription in resting T cells (101, 102). As such, Vpx 
could allow the establishment of latently infected cells, which, 
upon subsequent activation, would produce infectious virus that 
can expand the pool of infected (including latently infected) T 
cells. Only HIV-2 and some SIVs (notably those that are used in 
the macaque models) contain Vpx (103, 104). Although HIV-1 
does not encode Vpx, the virus is susceptible to the infectivity 
enhancement provided by the SIV accessory protein (105, 106). 
As such, while SAMHD1 seems to play a key role in a strategy 
of the immune system to avoid immune cellular responses upon 
viral infection, it also represents a key difference between the HIV 
infection of human patients and the NHP animal model (107).
Rhesus macaques infected with either the reference swarm 
SIVmac251 or with the SIVmac251-derived infectious molecular 
clone SIVmac239 accurately reproduce several aspects of human 
HIV infections, including sustained, high VLs, immediate and 
progressive depletion of mucosal CD4+ T cells, and chronic 
immune activation (56, 57). As such, this model is most widely 
used in a wide variety of cure-based studies. SIVmac239/251-
infected Chinese RMs represents another model of interest for 
cure research. Compared to Indian RMs, Chinese RMs have lower 
acute and chronic VLs, more closer to HIV-1 infected humans, 
and as such, SIV infection can be more readily controlled in 
Chinese RMs than in Indian RMs (67, 108).
Other macaque models have been also used to investigate the 
viral reservoirs. PTMs infected simultaneously with SIV/17E-Fr 
and SIV/Delta B670 represent a model of pathogenic infection, 
whereby the animals progress to AIDS within 3  months, with 
most animals developing central nervous diseases (109). This 
model is susceptible to tritherapy, which can suppress virus to 
below 50 copies/ml and was utilized to identify various anatomic 
sites of latently infected CD4+ T cells (27). It was also used to 
show that ART reduces both vRNA levels in cerebrospinal fluid 
to below the limit of detection (50 copies/ml), similar to vRNA 
levels in plasma, and inflammation in the central nervous system 
(CNS), suggesting early ART benefits levels of virus replication in 
the CNS and pointing to a strategy to mitigate neurological disor-
ders that develop during chronic infection (9, 110). This model of 
neuro-AIDS was used for the study of the anatomic reservoir of 
the brain as well as the macrophage reservoir (27, 109).
Cynomolgus macaques represent another NHP model of cure 
research, albeit its use is more limited than that of RMs. SIVmac-
infected CMs have intermediate peak VLs and low chronic VLs 
and, as such, are vastly easier to control with ART (76). This 
model is extensively used in Europe for the experiments related 
to cure research (11, 77, 90).
Due to genetic differences between SIVs and HIV, SIVmac 
strains, similar to HIV-2 strains, are not susceptible to NNRTIs 
(95, 98). Furthermore, SIV infection results in the selection of 
different epitopes compared to HIV infection. To address these 
limitations, SIVmac strains have been engineered to share charac-
teristics from both types of viruses to maximize model potential. 
Such chimeric simian-human immunodeficiency viruses (SHIVs) 
were produced to include HIV-1 reverse transcriptase (RT) gene. 
Two RT chimeras have been produced thus far: RT-SHIVmac239 
and RT-SHIVmne, SIV containing the HIV RT for the viruses 
SIVmac239 and SIVmne, respectively. They both overcome 
the NNRTI block for use in RMs and PTMs, respectively (62, 
73, 111). Additionally, enhanced SHIV clones with HIV-1 Env 
proteins from transmitted/founder strains have been developed 
without passaging, thus providing a model for future studies 
aimed at neutralizing antibody development and testing (112).
While very useful for addressing these critical aspects of 
cure research, RT-SHIVs also have their limitations, including 
difficulty in suppressing virus replication with the same triple 
ART treatments used in humans (i.e., tenofovir/emtricitabine/
efavirenz) (12, 73). Since most of the genome is represented by 
the SIVmac239 backbone, these are limitations due to the use of 
SIVmac.
The conventional NHP models for cure research based on the 
use of SIVmac recapitulate most of the characteristics of HIV-
infected patients. As HIV and SIV infections are both characterized 
by severe immunosuppression and significant alterations of the 
immune responses and since studies have shown that clearance of 
virus reactivated from the reservoir requires functional immune 
responses (113) and various cure approaches requires functional 
CTLs to eliminate the virus reactivated from the reservoirs, we 
recently focused on the development of alternative models for 
cure research that would permit us to refine the system, in order 
to be able to dissect the relative impact of various interventions 
on the reservoir.
Thus, we developed a RM model in which functional cure 
of SIV infection occurs spontaneously in 100% of infected 
monkeys in the absence of ART (60). In this model, infection of 
Indian RMs with SIVsab, the virus that naturally infects AGMs 
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in West Africa (114), results in a robust acute viral replication 
and a massive CD4+ T cell depletion. Control occurs between 2 
and 3 months postinfection and is maintained indefinitely (60). 
Virus control is progressively consolidated, and SIVsab infection 
eventually becomes latent in RMs, as documented by the use of a 
single copy assay (61). Consequently, residual immune activation 
persists throughout the first year of infection before returning to 
preinfection levels. As a result of complete virus control, mucosal 
CD4+ T cells are slowly restored, reaching preinfection levels after 
4 years postinfection (60). Furthermore, all biological and clinical 
markers of SIV infection (microbial translocation, immune acti-
vation, and apoptosis) are resolved and the animals serorevert by 
2 years postinfection. This robust and persistent virus control can 
be reverted by the in vivo depletion of CD8+ cells, while restored 
CD8+ cells control the rebounding virus (60). In this model, virus 
control is not due to its inability to replicate, as the serial passage 
of the reactivated virus to naïve RMs resulted in very robust levels 
of viral replication, which were similar to those observed with the 
parental virus, clearly demonstrating that the controlled virus is 
replication-competent (61). This model, in which a very robust 
control of the virus by functional immune responses occurs with-
out the complexity of ART, is an ideal setting for the screening of 
various strategies aimed at reactivating the virus from reservoirs 
by allowing the dissection of the effects of various reversing 
agents and of the corresponding immune responses without the 
confounding factors of ART and a weakened CTL response.
NHP MODeLS FOR CURe ReSeARCH: 
APPLiCATiONS
Use of the NHP Models to establish 
Pathogenesis Paradigms
The NHP models for AIDS research decisively contributed to 
the establishment of key paradigms of HIV pathogenesis, and it 
is likely that they will play a central role in cure research. Yet, 
initially, the field was relatively reluctant to consider NHPs for 
testing therapies requiring ART coverage, because SIV and SHIV 
infections were relatively difficult to control with tritherapy (12, 
53, 96–98), and as discussed above, residual virus replication is 
a major roadblock for studying virus reservoirs. However, with 
the renewed interest in cure research and the use of NHP mod-
els in this niche, complete suppression of VL and a noticeable 
effect on the viral reservoir were rapidly achieved by employing 
various aggressive ART regimens (9, 97, 110, 115). The original 
drug regimens used for the complete control of viral replica-
tion in macaques were complex and included a combination 
of emtricitabine (FTC), tenofovir (TDF), and raltegravir (RAL) 
with ritonavir-boosted darunavir and even maraviroc (97). 
With the advent of dolutegravir (DTG) and a coformulation of 
the above drugs, it was reported that control of SIVmac repli-
cation can be achieved in RMs with a tritherapy regimen (i.e., 
FTC + TDF + DTG) (115, 116). The ability to suppress SIVmac 
in RMs to the same levels of suppression seen in HIV-1-infected 
patients dramatically improved the prospects of cure research, 
allowing studies on reservoir seeding (116) or testing virus reac-
tivation strategies (112).
One of the key obstacles for cure research is that the virus res-
ervoir is established very early following infection. While this was 
postulated for quite a while based on results in vaccine studies, it 
was only recently directly proven (116). Thus, very rapid initiation 
of suppressive ART in RMs on days 3, 7, 10, and 14 after intrarec-
tal SIVmac251 infection showed that only treatment with ART 
on day 3 blocked the emergence of viral RNA and proviral DNA 
in peripheral blood and substantially reduced levels of proviral 
DNA in LNs and gastrointestinal mucosa compared to treatment 
at later time points. Furthermore, treatment on day 3 abrogated 
the induction of SIV-specific humoral and cellular immune 
responses. Yet, when ART was interrupted after 24 weeks of fully 
suppressive therapy, virus rebounded in all animals, including 
those that were treated on day 3. However, the day 3-treated RMs 
had a delayed virus rebound compared to those treated on days 7, 
10, and 14. The time to viral rebound correlated with total viremia 
during acute infection and with proviral DNA at the time of 
ART discontinuation. Altogether, these results demonstrated an 
extremely rapid seeding of the viral reservoir in RMs, during the 
“eclipse” phase, prior to detectable viremia, pointing to the dif-
ficulty of HIV eradication (116). Furthermore, the observed delay 
in virus rebound in monkeys treated very early during infection 
raises the question of whether or not a prolonged therapy will 
have a discernable impact on the size of the reservoir and on the 
ability to control viral rebound at cessation of ART, as reported 
with “Mississippi baby” (40) or the “Visconti” posttreatment 
controllers (43). In other studies whereby SIVmac251-infected 
RMs were given ART at 4  h, 7  days, or 14  days postinfection, 
it was shown that ART given at 4  h postinfection resulted in 
drastically lower virus replication and dissemination in the gut 
and lower plasma virus load 2 weeks following treatment com-
pared to 7 and 14 days postinfection, further supporting a rapid 
establishment of the reservoir (78, 90) and calling for a very rapid 
therapeutic intervention in HIV-infected patients. Unfortunately, 
the drawback of these observations is that in the vast majority of 
HIV-infected patients, it is virtually impossible to initiate ART so 
early postinfection.
One of the very important applications of the NHP models 
of AIDS with major impact on cure research is the study of 
residual viral replication in patients on ART. Studies employing 
ultrasensitive viral quantitation assays reported that in treated 
patients, the initial rapid virus decay is followed by a very slow 
decay (stage III of virus decay and even stage IV decay that is 
likely persistent during the lifespan of the infected patient) 
(117, 118). A key question in the field is whether or not this 
detectable virus (7–10  copies/ml) is replication-competent and 
can contribute to reservoir reseeding. There is also a debate as 
to whether virus persistence seen during successful ART is the 
result of incomplete suppression of virus replication or residual 
production of virus from long-lived, chronically infected cells 
(27, 38, 119–121). Persistent virus replication under ART may 
result in the development of resistance against the drugs used to 
suppress the virus, requiring the addition of more toxic drugs 
or, in extreme cases, resulting in complete drug failure. Though 
these studies can be done in humans, they have major limitations 
as they cannot thoroughly investigate the sources of the residual 
virus, such investigations requiring access to multiple tissue sites. 
January 2016 | Volume 7 | Article 126
Policicchio et al. Animal Models for HIV Cure Research
Frontiers in Immunology | www.frontiersin.org
The use of the NHP model, in which we can sacrifice the animals 
and extensively collect multiple tissue sites and cell types, allows 
us to understand what the specific “sanctuary” reservoir tissues 
are (i.e., the locations where the virus is not suppressed), as well 
as the sources of virus reactivation and resistance.
Use of the RT-SHIV/NHP models represents the most 
efficient method to address these aspects of viral persistence 
under ART. Since the experimental inoculum is thoroughly 
characterized when infectious molecular clones are employed, 
experimental infections with a known inoculum followed by the 
administration of potent ART, frequent sampling, and extensive 
sequencing permit a thorough assessment of virus evolution 
under ART as a surrogate of virus replication. Multiple studies 
utilizing the PTM model infected with various RT-SHIVs have 
documented that viral evolution occurs under ART (75, 122, 
123).
Studies in the RT-SHIV model have also shown that viral 
diversity does not decrease during suppressive ART and that the 
virus levels present prior to initiation of therapy influence the 
development of resistant strains (64, 75). They have also shown 
that upon ART reinitiation following interruption, the rate of 
viral decay matches the decay seen upon initial ART adminis-
tration, reflecting that wild-type virus becomes integrated and 
emerges following ART interruption (73–75). Further studies will 
be needed to better characterize the fate of various viral reservoirs 
in patients receiving ART.
Use of NHP Models to Test Latency 
Reversal Agents
The virally suppressed SIV/RM models have allowed the testing 
of several latency reversal agents (LRAs) to determine their ability 
to reactivate latent virus and assess the impact of this strategy on 
the size of the overall reservoir. Administration of the histone 
deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid 
(SAHA) to SIV-infected ART-suppressed RMs induced a very 
limited amount of virus reactivation, in spite of inducing a dis-
cernable increase in histone acetylation, indicating that repeated 
HDACi administrations may be necessary to see a more robust 
effect (67, 124). The NHP model can further be employed to test 
various hypotheses based on ex vivo experiments using HDACi. It 
was recently reported that administration of HDACi (particularly 
romidepsin, and to a lesser extent, panobinostat and SAHA) 
may significantly impact T-cell effector functions through either 
rapid suppression of cytokine production from viable T cells or 
through induction of selective death of activated T cells (125). 
As such, HDACis impaired CTL-mediated IFN-γ production, as 
well as the elimination of HIV-infected or peptide-pulsed target 
cells. It was, therefore, concluded that treatment with HDACis 
to mobilize the latent reservoir could have unintended negative 
impacts on the effector functions of CTL, which could influence 
the effectiveness of HDACi-based eradication strategies, by 
impairing elimination of infected cells (125). In vivo studies in 
NHPs are needed to confirm these ex vivo results.
Auranofin, a gold-based compound used to treat rheumatoid 
arthritis and a potential LRA, was also tested in RMs. It was 
reported that RM exposure to auranofin resulted in a reduction 
of the viral reservoir, followed by a delay in virus rebound at 
the cessation of ART compared to the untreated group (126). 
Furthermore, administration of auranofin together with the 
experimental chemotherapeutic agent buthionione sulfoximine 
(BSO) prior to ART cessation resulted in a rebound of VLs fol-
lowed by control of the virus to undetectable levels and minimal 
immune activation for 2 years following ART cessation (127, 128).
Simian immunodeficiency virus-infected RMs were also used 
for testing protein kinase C (PKC) activators, such as prostratin 
or bryostatin. While, to date, there are no published studies 
reporting these results, PKC activators have been shown to have 
therapeutic effects at doses that are very close to toxic levels 
and cannot be administered for prolonged rounds of treatment 
without substantial toxicity or even death of the animals. Thus, 
PKC activators need further testing to conclude their usefulness 
for virus reactivation strategies.
All these experiments demonstrate that the NHP models 
proved their usefulness for testing virus reactivation strategies 
and will continue to be used for future studies. Particularly for 
the field of virus reactivation experiments, the use of the macaque 
models in which virus control occurs either spontaneously 
or posttreatment may be very useful for screening LRAs in an 
environment with functional immune responses and without the 
complexity of ART (52).
Use of NHP Models to Test 
Transplantation Strategies
One avenue of cure research currently being explored is stem cell 
transplant following total body irradiation in an effort to mimic 
the cure seen by the Berlin patient (44). To this end, RMs were 
infected with SHIV and treated with ART to reduce viral replica-
tion prior to total body irradiation and engraftment of autologous 
hematopoietic stem cells isolated from the respective RMs prior 
to infection. At 40–75 days post-graft, ART was stopped. In two 
of three RMs, rapid viral rebound occurred, with the third RM 
exhibiting no plasma viral RNA 2  weeks following ART inter-
ruption (129). While the therapeutic success was limited, this 
study demonstrated that the replacement of the hematopoietic 
compartment was insufficient to eliminate host viral reservoirs. 
Even more important, it provided a new model for studying 
eradication strategies.
Use of NHP Models to Test Strategies 
Aimed at Controlling Persistent immune 
Activation
Chronic inflammation and immune activation were reported to 
be the key obstacles for cure research. Chronic immune activa-
tion persists in patients on ART (35, 130). The pool of activated 
cells represents one of the key sources of residual viremia 
(“homeostatic proliferation”) (1). Furthermore, activated CD4+ 
T cells are susceptible to infection, and increasing the pool of 
susceptible cells may favor reservoir reseeding, thus representing 
a key determinant of viral persistence (1).
The sources of chronic immune activation and inflammation 
in patients receiving ART are not completely known. While the 
virus clearly induces immune activation itself, it is also controlled 
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with ART. Other major triggers of chronic immune activation are 
microbial translocation, coinfections with cytomegalovirus and 
other copathogens, or ART toxicity (131). Depletion of CD4+ T 
cells (through either T cell activation and apoptosis or through 
direct effect of the virus itself) may be responsible for inflamma-
tion (132). Thus, CD4+ T cell loss leads to further mucosal dam-
age, resulting in increased microbial translocation and immune 
activation (133). In the pool of the CD4+ cells that are depleted, 
Th17 cells that are responsible for gut integrity and defense 
against microorganisms are preferentially targeted by HIV/SIV 
infection, resulting in the disruption of mucosal integrity and 
increased microbial translocation (134–136).
In addition to contributing to the virus reservoir, Tregs like-
wise play a role in both peripheral tolerance as well as control-
ling immune activation (137). Administration of Ontak, a drug 
that partially depletes Tregs to chronically SIV-infected AGMs, 
boosted both viral replication and immune activation, suggesting 
that Tregs may play a role in controlling the virus (138). Other 
studies have shown that Tregs critically contribute to the devel-
opment of fibrosis and that Treg blockade with an anti-CTLA-4 
antibody results in increased effector functions for CD4+ and 
CD8+ T cells in SIV-infected RMs (139, 140). Further studies are 
needed to understand the impact of Treg on the outcome of HIV/
SIV infections.
Various treatments to reduce or minimize residual immune 
activation are being tested, and NHP models are central for such 
studies (141). Several studies have investigated the usefulness 
of interleukin (IL)-7 treatment to limit cell depletion when 
administered alone or with IFN-α. These studies have shown that 
IL-7 effectively prevented the complete depletion of CD4+ T cells 
when administered during acute infection (142). IL-7 increased 
proliferative capabilities and induced sustained increases of 
PBMC counts when administered in “clustered” doses (143); 
finally, IL-7 treatment prevented lymphopenia associated with 
IFN-α treatment while stimulating CD8+ CTLs against SIV (144).
Another potential therapeutic intervention is the use of IL-21 
to restore/preserve T helper 17 (Th17) cells, which are responsible 
for mucosal integrity (135, 145). IL-21 administration to ART-
suppressed RMs infected with SIVmac restored Th17 and Th22 
cells, reduced immune activation in the blood and rectum, and 
decreased levels of CD4+ T cells harboring replication-competent 
virus (146). Also, IL-21 administration was reported to reduce 
the size of the viral reservoir (146). Another study showed that 
the administration of IL-21 combined with probiotics to ART-
treated SIV-infected RMs improved recovery and maintenance of 
Th17 cells, contributing to reduced microbial translocation (147). 
Similarly, when probiotics were administered to SIV-infected 
PTMs on ART, levels and functionality of gut CD4+ T cells and 
APCs were increased, with a noticeable decrease in fibrosis in 
colonic lymphoid follicles (148).
In addition to cytokine treatment for control of immune 
activation, other strategies directly target microbial transloca-
tion and the potential impact on chronic immune activation 
and inflammation. Such strategies involved lipopolysaccharide 
(LPS)-sequestering in the gut with sevelamer (149). Sevelamer 
administration to acutely infected macaques resulted in a 
reduction of immune activation, inflammation, and coagulation 
biomarkers (72). The second strategy involves administration 
of intraluminal antibiotics, such as rifaximin (a semisynthetic, 
broad-spectrum antibiotic with poor bioavailability and is 
currently used to treat traveler’s diarrhea and hepatic encepha-
lopathy) (150, 151). Rifaximin administration, in combination 
with the anti-inflammatory agent sulfasalazine, to acutely 
SIV-infected PTMs transiently and moderately improved the 
key parameters of SIV infection. (152). There is no information 
regarding the efficacy of these treatments in chronically infected 
RMs on ART. For these studies aimed at controlling microbial 
translocation-induced immune activation, PTMs are probably 
a better model than RMs, as gut damage is more extensive in 
SIV-infected PTMs. Moreover, PTMs have a higher propensity 
for gastrointestinal disease, even in the absence of SIV infection 
(153). Considering that previously published studies reported a 
relatively limited duration of therapeutic effect and that chroni-
cally infected patients will need to receive these therapies as life-
lasting interventions, it is likely that the therapeutic applicability 
of these interventions will be limited. Overall, these studies point 
to the NHP models as critical tools for testing various treatments 
to reduce immune activation.
Use of NHP Models for vaccine Studies 
with Applicability to Cure Research
Development of an AIDS vaccine is considered the ultimate 
approach in order to control the epidemic. However, in spite of 
significant progress over the last decade, a vaccine against HIV 
is not available. In the early 2000s, it was considered that even 
a vaccine that does not prevent the infection but will control 
viral replication may be useful for controlling the epidemic 
(154). With the renewed interest in cure research, this concept 
was translated to the cure field. Vaccines that control virus 
replication are considered useful and will enable us to study 
the mechanisms of the functional cure of HIV infection. The 
only vaccine currently available proven to induce functional 
cure in RMs is based on the use of the cytomegalovirus (CMV) 
vectors. The concept behind the use of the CMV vectors is that 
infection with CMVs is benign in immunocompetent patients 
and results in persistent, life-long, and highly biased T cell effec-
tor memory (TEM) CD4+ and CD8+ T cell responses (155, 156). 
The replicative nature of the CMV vector and its subsequent 
TEM stimulation, along with the fact that TEM are the major T 
cell type found at mucosal effector sites (157), make the CMV 
vectors ideal candidate HIV vaccines. Indeed, rhesus CMV 
(RhCMV)/SIV vectors expressing SIV Gag, Rev/Nef/Tat, and 
Env administered to RMs prior to low-dose intrarectal infection 
with SIVmac239 conferred some protection to SIV challenge 
(156). More importantly, 50% of the RMs vaccinated with the 
RhCMV vectors, after experiencing an initial burst of viremia 
following first challenge, rapidly controlled infection through 
an immune-mediated partial control of SIV (158) and were 
functionally cured of SIV. Virus control was very robust, result-
ing in undetectable levels of vRNA in multiple tissues. In these 
RMs, CD8+ cell depletion did not result in a virus rebound nor 
did transfusion of 30 × 106 cells from the cured RMs to naïve 
RMs result in infection. It has now been shown the RhCMV/
TABLe 3 | Different mouse models utilized in cure research.a
Hiv/SCiD-hu Hiv/hu-HSC Hiv/BLT
Methods for 
production
SCID mice 
implanted with 
fetal human 
thymus/live
NOD/NSG 
mice irradiated, 
injected with 
human HSCs
NOD/SCID mice 
irradiated, implanted 
with fetal human 
thymus/live, injected 
with HSCs
Timeframe 
needed 
for mouse 
production 
(prior to 
infection)
5–7 months 
from time of 
birth
2–3 months 
from time of 
birth
5–7 months from time 
of birth
Cellular 
composition 
following 
reconstitution
T cells T and B cells 
and DCs
T and B cells, 
monocytes, 
macrophages, NK cells, 
DCs
Degree of 
colonization
Limited to 
thymus/live 
implant
Murine lymph 
organs and 
bone marrow
Murine lymph organs, 
rectum, vagina, gut, 
bone marrow
Length 
infection 
maintained
Grafts last 
approx. 1 year
6–7 months >1 year
Plasma vRNA 104–105 Up to 107 104–105
aTraggiai et al. (164), Bonyhadi and Kaneshima (165), Brainard et al. (166), McCune 
et al. (167), Nischang et al. (168), Baenziger et al. (169), Berges et al. (170), and 
Pettoello-Mantovani et al. (171).
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SIV vector elicits distinct patterns of CD8+ T cell epitope rec-
ognition not normally seen during SIV infection (159). As such, 
RMs vaccinated with RhCMV-based SIV vaccines are an ideal 
setting for the study of the correlates of the functionally cured 
SIV infection.
USe OF MiCe FOR CURe ReSeARCH
Humanized mice represent an important tool for HIV cure 
research. Of the various types of humanized mice developed 
to date, the most commonly used types are severe combined 
immune deficiency human (SCID-hu), human hematopoietic 
stem cells (hu-HSC), and bone-liver-thymus (BLT) (Table  3). 
All three models are readily infected following HIV-1 challenge. 
SCID-hu mice are generated when fetal human thymus and liver 
fragments are implanted into mice lacking B and T cells, thus 
preventing rejection of the human tissue. Following implanta-
tion, the SCID-hu mouse is reconstituted with human thymo-
cytes and naïve T cells. The drawbacks of the SCID-hu mouse 
model are the following: major surgery with human fetal tissue is 
required, the mice lack a primary immune response, reconstitu-
tion with human cells is focused around the implant, and the 
reconstituted cells do not efficiently spread into the periphery 
(50). Hu-HSC mice are sublethally irradiated non-obese diabetic 
(NOD) or NOD SCID gamma (NSG) that are then injected with 
human HSC, allowing for a more thorough reconstitution with 
human cells than SCID-hu mice. These mice are able to generate 
a near complete human immune system. The immune responses 
generated in this model are, however, neither robust nor HLA-
restricted (50). BLT mice are a combination of SCID-hu and 
hu-HSC mice, whereby NOD or NSG mice are sublethally irra-
diated, implanted with fetal human liver and thymus fragments, 
and then injected with human HSC. This results in a thorough 
reconstitution of human HLA-restricted cells throughout the 
mice in most organs, with improved mucosal immunity and a 
more robust immune response compared to SCID-hu and hu-
HSC mice (160–162). There are several limitations of the BLT 
mouse model, which are as follows: (i) it requires major surgery 
and the implantation of human fetal tissue, (ii) a long waiting 
period is needed until full reconstitution is observed, (iii) the 
development of graft-versus-host disease occurs approximately 
6  months post-engraftment, and (iv) BLT mice are unable to 
develop high levels of hypermutated, class-switched IgG anti-
bodies (163).
SCID-hu mice have played an important role in elucidating 
the characteristics of latency development during the early stages 
of infection. The exact mechanisms behind the development of 
viral latency have yet to be established, but one theory is that 
activated CD4+ T cells become infected by the virus but transi-
tion into a resting state before the host immune response or the 
virus itself kills the cell (172, 173). SCID-hu mice have been used 
to prove viral latency, which can also occur when thymic CD4+ 
CD8+ T cells are infected by HIV-1 and transited into CD4+ T 
cells (174). Furthermore, this model has been instrumental in the 
initial understanding of latently infected cells and was the vehicle 
utilized in the earliest latency-depleting experiments (175–178). 
It was shown that prostratin and IL-7, both of which are currently 
tested as LRAs, could activate HIV-1 from latently infected cells 
in the SCID-hu model (175, 176). Furthermore, it was shown that 
these drug-induced activated cells could be targeted for elimina-
tion with an anti-HIV envelope immunotoxin, one of the earliest 
“shock and kill” experiments (177).
Hu-HSC mice have significantly advanced research on 
understanding HIV latency. Choudhary et  al. have shown that 
replication-competent HIV-1 persists in CD4+ T cells in mice 
receiving ART, providing an avenue for strategies targeting the 
viral reservoir (179). Further, the hu-HSC mouse model was 
utilized to test the effectiveness of a CCR5-targeting zinc-finger 
nuclease in controlling HIV-1 infection. Zinc-finger nuclease-
expressing CD34+ cells were inserted into HIV-1-infected hu-HSC 
mice resulting in a selection of the virus for CCR5-negative cells, 
a reduction of HIV-1 (VLs), and a preservation of human cells 
(180). Hu-HSC mice were also used to test human T cell-targeted 
small interfering RNA (siRNA) constructs that deliver anti-CD4, 
-CCR5, -vif, and -tat siRNAs. It was shown that the infected 
hu-HSC mice which received the constructs had 30-fold lower 
VLs compared to the control group (181). Finally, it was shown 
that treatment with both anti-HIV envelope antibodies and three 
types of HIV latency reversing agents (vorinostat, I-BET151, and 
CTLA) resulted in mice controlling VLs and a decrease in the 
rebound frequency of the virus (182). As such, hu-HSC mice have 
been a useful model for identifying potential LRAs.
Unlike SCID-hu and hu-HSC mice, BLT mice are able to 
recapitulate a primary immune response against HIV-1 infection 
while remaining susceptible, thus representing the most efficient 
and complete mouse model for HIV studies. The BLT mouse 
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model is readily infected by HIV-1; VLs can be readily controlled 
with intensive ART regimens in this model, with return of VLs 
upon ART cessation; and PBMCs isolated from the mice can be 
induced to express virus ex vivo (183, 184). Similar to humans 
and macaques, CD4+ T cell depletion is strain-dependent 
(185). BLT mice have also been used to test a CCR5-targeted 
RNA-interference (RNAi) treatment that provided a protective 
effect against HIV-1 replication (186). It was also shown that a 
targeted, cytotoxic anti-HIV immunotoxin therapy dramatically 
depleted the number of productively infected cells in various 
organs when combined with ART in BLT mice (187). Recently, 
engineered mice have been developed to contain exclusively T 
lymphocytes (TOM) or macrophages (MOM). As such, these 
models can be used to better assess the in vivo distribution of 
the reservoir (188).
Altogether, mouse models can be used to address quintes-
sential questions of cure research, but come with a specific set 
of limitations, including (1) incomplete colonization of murine 
tissues with human cells, especially at the mucosal sites (albeit 
at a lesser degree in the BLT model); (2) a more limited deple-
tion of CD4+ T cells in tissues (185); (3) long waiting periods for 
reconstitution with human cells following surgery; and (4) size 
limitations relative to experimental demand. This last limitation 
is particularly important vis-à-vis cure research, as the assessment 
of the reservoir virus and its inducibility can only be performed 
on large amounts of cells, normally an order of magnitude higher 
than what can be routinely obtained from mice. As such, the 
demand for more frequent and larger samples offsets the lower 
cost of the model by necessitating the sacrificing of a larger num-
ber of mice. Overall, the advantages of the models offset these 
limitations, but still necessitate the use of larger animal models 
for specific experiments.
OTHeR MODeLS FOR CURe ReSeARCH
Feline immunodeficiency virus (FIV) infection in domestic 
felines represents a large-animal model of lentiviral-induced 
immunodeficiency and shares similarities in pathogenesis with 
that of HIV-1 in humans (51, 189, 190). Furthermore, the FIV 
model represents the only naturally occurring model of immu-
nodeficiency (191). Infected felines exhibit high acute viremia, 
depleted CD4+ and CD8+ cells, and the establishment of chronic 
infection, whereby the virus is controlled naturally (189). Similar 
to HIV-1-infected patients, CD4 counts continue to decrease 
until terminal illness, whereby cell-free viral RNA levels increase, 
immune dysfunction occurs, and opportunistic infections appear 
as the cat develops feline AIDS (FAIDS) (189). The FIV model 
had some value for the development and testing of antiretroviral 
drugs, particularly nucleoside reverse transcriptase inhibitors 
(NRTIs) (192). The FIV model can be also used to explore the 
potentiality of host restriction factors, as evidenced by transgen-
esis of the RM TRIMCyp into the cat germline resulting in feline 
resistance to FIV replication (193). This model has also been used 
to test the effectiveness of the LRA SAHA, observing increased 
levels of cell-associated viral RNA, one measurable point of cell-
free RNA, and decreased levels of viral DNA (194).
Though progress has been made in understanding the FIV 
model, it has its own set of limitations, including the absence 
of certain accessory genes in FIV that are seen in HIV-1 (while 
encoding its own set of open reading frames not present in 
primate lentiviruses) (195); FIV utilizes CD134 instead of 
CD4 as the main binding receptor (196), 134, allowing FIV to 
infect B cells and CD8+ T cells in addition to CD4+ T cells and 
macrophages (197). As such, the target cells of FIV and HIV/
SIV are different and with the structure of the reservoir being 
different, the applicability of the FIV model for cure research is 
likely limited.
CONCLUSiON
There is an acute need for an HIV cure and ART cannot provide 
it. Novel research with LRAs and other strategies is bringing us 
closer to a functional cure. Use of animal models as critical tools 
for cure research permits preclinical testing of the plethora of 
interventions that are currently contemplated for a cure strat-
egy. The vast majority of these new strategies are tested in the 
various existing animal models for HIV-1. Humanized mouse 
models infected with HIV-1 allow for lower maintenance costs 
in a genetically identical model that directly mimics the human 
immune system but are difficult to produce, unable to be bred, 
and have limitations in tissue colonization and tissue demand 
relative to size. FIV infection of cats has only a limited applicabil-
ity for cure research due to the key differences in the structure of 
the reservoir. SIV-infected monkeys are larger than both mouse 
and feline models, offering both a natural host of infection as 
well as a pathogenic model with a similar physiology and disease 
progression to HIV-infected humans but at the price of higher 
maintenance costs, harder acquisition of susceptible species, 
and the use of a different, yet genetically similar virus strains. 
Fine tuning of each model type, combined with novel research 
techniques aimed at “shocking and killing” latent virus and the 
development of immune-based therapies, may fuel HIV cure 
research.
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